Cargando…

Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study

BACKGROUND: In vitro data suggests that suboptimal initial vancomycin exposure may select for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infections. However, no clinical studies have evaluated the relationship between initial vancomycin exposure and emergence of hVISA. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martirosov, Dmitriy M., Bidell, Monique R., Pai, Manjunath P., Scheetz, Marc H., Rosenkranz, Susan L., Faragon, Corey, Malik, M., Mendes, R. E., Jones, R. N., McNutt, Louise-Anne, Lodise, Thomas P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540561/ https://www.ncbi.nlm.nih.gov/pubmed/28764660 http://dx.doi.org/10.1186/s12879-017-2609-0

Ejemplares similares

Vancomycin (VAN) Combinations with Β-Lactams (BLs) against Methicillin-Resistant Staphylococcus aureus (MRSA), Heterogeneous Intermediate-Level Resistance to Vancomycin (hVISA) and Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Tran, Kieu-Nhi, et al.
Publicado: (2017)

1249. Metabolomic Profile of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) in Latin-American MRSA Isolates
por: Castro-Cardozo, Betsy E, et al.
Publicado: (2021)

Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA
por: Lai, Chih-Cheng, et al.
Publicado: (2017)

Modulating Activity of Vancomycin and Daptomycin on the Expression of Autolysis Cell-Wall Turnover and Membrane Charge Genes in hVISA and VISA Strains
por: Cafiso, Viviana, et al.
Publicado: (2012)

721 Decreasing Prevalence of Vancomycin-Heteroresistance (hVISA) among Methicillin-Resistant Staphylococcus aureus (MRSA) Blood Isolates over 10 years: Potential Impact of Vancomycin Treatment Guidelines
por: Khatib, Riad, et al.
Publicado: (2014)

Different Vancomycin-Intermediate Staphylococcus aureus Phenotypes Selected from the Same ST100-hVISA Parental Strain
por: Di Gregorio, Sabrina, et al.
Publicado: (2017)

The Emperor’s New Clothes: Prospective Observational Evaluation of the Association between the Day 2 Vancomycin Exposure and Failure Rates among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE)
por: Lodise, Thomas P, et al.
Publicado: (2017)

Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
por: Park, Jung Wan, et al.
Publicado: (2019)

Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Su, Michelle, et al.
Publicado: (2021)

Vancomycin resistance among MRSA
por: Kumar, V. Anil
Publicado: (2012)

Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility
por: Yang, Chien-Chang, et al.
Publicado: (2018)

Antibiotic Exposure Leads to Reduced Phage Susceptibility in Vancomycin Intermediate Staphylococcus aureus (VISA)
por: McCallin, Shawna, et al.
Publicado: (2022)

2010. A Significant Reduction in Empiric Vancomycin Days of Therapy for Suspected MRSA Pneumonia in Adult Non-ICU Patients After Implementation of a Rapid MRSA Nasal PCR Test with Antimicrobial Stewardship Intervention
por: Markoski, Nikola, et al.
Publicado: (2019)

1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus
por: Abdul-Mutakabbir, Jacinda, et al.
Publicado: (2019)

673 Comparative Effectiveness of Vancomycin vs Early Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg/L: A Multicenter Evaluation
por: Moise, Pamela, et al.
Publicado: (2014)

Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections
por: Neoh, Hui-min, et al.
Publicado: (2007)

Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas P, et al.
Publicado: (2019)

Detection of Staphylococcus aureus with an intermediate profile to vancomycin (VISA) isolate from Santa Maria, RS
por: Marques, Jaciane Baggiotto, et al.
Publicado: (2013)

1928. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas, et al.
Publicado: (2018)

Aortic Root Abscess with Aorta to Right Atrium Fistula due to Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Hankinson, Stephen J., et al.
Publicado: (2019)

Intermediate Vancomycin Susceptibility in a Community-associated MRSA Clone
por: Graber, Christopher J., et al.
Publicado: (2007)

Reduced vancomycin susceptibility in porcine ST9 MRSA isolates
por: Kwok, Gabriella M. L., et al.
Publicado: (2013)

Acute MRSA Sinusitis with Intracranial Extension and Marginal Vancomycin Susceptibility
por: Kumar, Parvathi S., et al.
Publicado: (2013)

Serum levels of vancomycin: is there a prediction using doses in mg/kg/day or m(2)/day for neonates?
por: Romanelli, Roberta Maia de Castro, et al.
Publicado: (2016)

1568. The Pharmacodynamic–Toxicodynamic Relationship of AUC and CMAX in Vancomycin-Induced Kidney Injury
por: Avedissian, Sean N, et al.
Publicado: (2019)

Enteral Vancomycin to Eliminate MRSA Carriership of the Digestive Tract in Critically Ill Patients
por: Buitinck, Sophie H., et al.
Publicado: (2022)

Intermediate-Type Vancomycin Resistance (VISA) in Genetically-Distinct Staphylococcus aureus Isolates Is Linked to Specific, Reversible Metabolic Alterations
por: Alexander, Elizabeth L., et al.
Publicado: (2014)

Comparison of Outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Vancomycin vs. Non-Vancomycin Anti-MRSA Therapy
por: Stoneking, Carolyn, et al.
Publicado: (2017)

Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA
por: Bhise, Ketki, et al.
Publicado: (2018)

474 Ceftaroline Salvage Therapy for MRSA Bacteremia Following Vancomycin Failure
por: Pettit, Natasha, et al.
Publicado: (2014)

1239. Ceftaroline versus Vancomycin as First-Line Therapy for MRSA Bacteremia
por: Kamath, Meghan, et al.
Publicado: (2021)

Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
por: Lodise, Thomas P, et al.
Publicado: (2022)

Pharmacokinetic and Biomarker Quantification Studies on Vancomycin-Loaded PEGylated Liposomes and Its Potential to Reduce Vancomycin-Induced Kidney Injury: A Rat Study
por: Joshi, Medha D., et al.
Publicado: (2023)

Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Trinh, Trang D, et al.
Publicado: (2017)

Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection
por: Barlow, Ashley, et al.
Publicado: (2021)

Screening and detection of heterogenous vancomycin intermediate Staphylococcus aureus in Hospital Kuala Lumpur Malaysia, using the glycopeptide resistance detection Etest and population analysis profiling
por: Ramli, Siti Roszilawati, et al.
Publicado: (2012)

Impact of Vancomycin-Associated Acute Kidney Injury on Patient Outcomes in MRSA Bacteremia
por: Luther, Megan, et al.
Publicado: (2017)

Biopsy-Proven Acute Tubular Necrosis due to Vancomycin Toxicity
por: Shah-Khan, Farheen, et al.
Publicado: (2011)

160. Measuring the Impact of PCR-based MRSA Nares Screening on Vancomycin Use and Duration of Vancomycin Among Pneumonia Patients at an Academic Medical Center
por: Stromberg, Joseph, et al.
Publicado: (2023)

A Rare Case of Methicillin-Resistant Staphylococcus aureus (MRSA) Enterocolitis Treated With Oral Vancomycin
por: Tagliaferri, Ariana R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ejb2uujhnlfj2idm4rcvvif71